特發性嗜睡症治療市場：依藥物類別、通路和地區分類

Idiopathic Hypersomnia Treatment Market, By Drug Class, By Distribution Channel, By Geography

出版日期: 2026年04月27日 | 出版商:

Coherent Market Insights | 英文 152 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2026年，特發性嗜睡症治療市場規模估計為3.947億美元，預計2033年將達到7.096億美元。預計從2026年到2033年，該市場將以8.7%的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	3.947億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	8.70%	2033年市場規模預測：	7.096億美元

特發性嗜睡症是一種罕見的睡眠障礙，其特徵是即使睡眠充足或時間延長，白天仍過度嗜睡。患者也可能在夜間睡眠或午睡後難以醒來。雖然發作性睡病和特發性嗜睡症都屬於嗜睡症，但它們的區別在於睡眠起始快速動眼睡眠期（SOREMP）的數量，這可以透過睡眠多項生理檢查（PSG）等診斷測試來確認。發作性睡病患者在睡眠多項生理檢查（PSG）和多次睡眠潛伏期測試（MSLT）中會顯示兩個或兩個以上的SOREMP，而特發性嗜睡症患者則不會。雖然有一些針對特發性嗜睡症的症狀治療方法，例如提高警覺性，但目前尚無核准的藥物用於治療疾病。

市場動態

不斷增加的在研發線產品數量以及文明病病例的上升是推動全球特發性嗜睡症治療市場發展的關鍵因素。例如，2020年10月，Jazz Pharmaceuticals宣布其特發性嗜睡症治療藥物Xywav（鈣、鎂、鉀和鈉氧巴特）的3期臨床試驗取得了特發性，證實該藥物達到了主要終點（Epworth嗜睡症量表（嗜睡症）和關鍵次要終點[總體患者改善（PGIc）和特發性量表嚴重程度]。

本次考試的主要特點

本研究揭示了各個細分市場的潛在商機，並說明了該市場極具吸引力的投資提案矩陣。
此外，本研究還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要參與者採取的競爭策略的重要見解。
本研究根據以下參數對全球特發性嗜睡症治療市場的主要參與者進行了分析：公司概況、財務表現、產品系列、市場佔有率、分銷策略、主要發展、戰略和未來計劃。
透過利用本報告中的見解，企業行銷負責人和經營團隊將能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
這份「特發性嗜睡症治療市場」報告針對產業內的各種相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
透過分析全球特發性嗜睡症治療市場中使用的各種策略矩陣，相關人員將能夠更輕鬆地做出決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 亞太其他地區
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 南非
- 中非
- 北非

第7章競爭情勢

熱圖分析
公司簡介
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd.
- Jazz Pharmaceuticals, Inc.
- BIOPROJET
- Avadel Pharmaceuticals, Plc.
- GlaxoSmithKline plc,
- Pfizer Inc.
- Theranexus
- Fisher &Paykel Healthcare Limited
- Innovation Pharmaceuticals Inc.
- Drive DeVilbiss Healthcare LLC
- Merck &Co. Inc.

第8章

調查方法

簡介目錄

Product Code: CMI4306

Idiopathic Hypersomnia Treatment Market is estimated to be valued at USD 394.7 Mn in 2026 and is expected to reach USD 709.6 Mn by 2033, growing at a compound annual growth rate (CAGR) of 8.7% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 394.7 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	8.70%	2033 Value Projection:	USD 709.6 Mn

Idiopathic hypersomnia is a rare sleep disease that causes a person to be excessively sleepy during the day even after a good or prolonged night's sleep. It also causes difficulty in waking up among patients after a night sleep or a nap. Moreover, narcolepsy and idiopathic hypersomnia are both types of hypersomnia but there are differences, which can be observed by diagnostic tests such as Polysomnography (PSG) that lies in the number of sleep-onset REM periods (SOREMPs). Patients with narcolepsy have two or more SOREMPs from Polysomnography (PSG) and Multiple Sleep Latency Test (MSLT) results, whereas patients with idiopathic hypersomnia do not. There are symptomatic treatment such as increase wakefullness options available for idiopathic hypersomnia, while there is not a single approved drugs for this disease.

Market Dynamics

Rising number of pipeline products and increasing cases of lifestyle diseases are some of the major factors responsible for growth of the global idiopathic hypersomnia treatment Market. For instance, in October 2020, Jazz Pharmaceuticals announced positive topline results from a phase 3 study evaluating Xywav (calcium, magnesium, potassium, and sodium oxybates) for the treatment of idiopathic hypersomnia that showed that the trial met the primary point (measured Epworth Sleepiness Scale (ESS)) and key secondary end points [Patient Global Impression of Change (PGIc) and Idiopathic Hypersomnia Severity Scale (IHSS)].

Key features of the study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global idiopathic hypersomnia treatment market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Jazz Pharmaceuticals, Inc., BIOPROJET, Avadel Pharmaceuticals, Plc. GlaxoSmithKline plc, Pfizer Inc., Theranexus, Fisher & Paykel Healthcare Limited, Drive DeVilbiss Healthcare LLC, and Merck & Co. Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global idiopathic hypersomnia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global idiopathic hypersomnia treatment Market

Idiopathic Hypersomnia Treatment Market Segmentation

By Drug Class
- Stimulant Medications
- Non-stimulant wake-promoting Medications
- Sodium Oxybate
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Idiopathic Hypersomnia Treatment Market, By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
Key Players
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd.
- Jazz Pharmaceuticals, Inc.
- BIOPROJET
- Avadel Pharmaceuticals plc
- GlaxoSmithKline plc
- Pfizer Inc.
- Theranexus
- Fisher & Paykel Healthcare Limited
- Drive DeVilbiss Healthcare LLC
- Merck & Co., Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

CKD Stages Treatment Options
Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Pipeline Analysis
Market Trends
Recent Product Launch/Approvals
Cost of Treatment
Regulatory Scenario
PEST Analysis
Mergers, Acquisitions, and Partnerships
Epidemiology
Reimbursement Scenario (Medicare Part D Spending)

4. Global Idiopathic Hypersomnia Treatment Market, By Drug Class, 2021-2033 (USD Mn)

Introduction
- Market Share Analysis, 2026, and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Stimulant Medications
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Non-stimulant wake-promoting Medications
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Sodium Oxybate
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends

5. Global Idiopathic Hypersomnia Treatment Market, By Distribution Channel, 2021-2033 (USD Mn)

Introduction
- Market Share Analysis, 2026, and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospital Pharmacies
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Online Pharmacies
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Retail Pharmacies
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends

6. Global Idiopathic Hypersomnia Treatment Market, By Region, 2021-2033 (USD Mn)

Introduction
- Market Share Analysis, By Region, 2026, and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2033
North America
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026-2033 (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Mn)
- Market Size and Forecast, By Country, 2026-2033 (USD Mn)
  - U.S.
  - Canada
Latin America
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026-2033 (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Mn)
- Market Size and Forecast, By Country, 2026-2033 (USD Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026-2033 (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Mn)
- Market Size and Forecast, By Country, 2026-2033 (USD Mn)
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026-2033 (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Mn)
- Market Size and Forecast, By Country, 2026-2033 (USD Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026-2033 (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Mn)
- Market Size and Forecast, By Country, 2026-2033 (USD Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026-2033 (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Mn)
- Market Size and Forecast, By Country, 2026-2033 (USD Mn)
  - South Africa
  - Central Africa
  - North Africa

7. Competitive Landscape

Heat Map Analysis
Company Profiles
- Takeda Pharmaceutical Company Limited
  - Company Overview
  - Product Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Teva Pharmaceutical Industries Ltd.
  - Company Overview
  - Product Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Jazz Pharmaceuticals, Inc.
  - Company Overview
  - Product Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- BIOPROJET
  - Company Overview
  - Product Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Avadel Pharmaceuticals, Plc.
  - Company Overview
  - Product Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- GlaxoSmithKline plc,
  - Company Overview
  - Product Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Pfizer Inc.
  - Company Overview
  - Product Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Theranexus
  - Company Overview
  - Product Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Fisher & Paykel Healthcare Limited
  - Company Overview
  - Product Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Innovation Pharmaceuticals Inc.
  - Company Overview
  - Product Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Drive DeVilbiss Healthcare LLC
  - Company Overview
  - Product Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Merck & Co. Inc.
  - Company Overview
  - Product Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies